AAZ |
acetazolamide |
AD |
Alzheimer’s Disease |
AEs |
anion exchangers |
APP |
amyloid protein precursor |
Aβ |
amyloid-β peptide |
BBB |
blood-brain barrier |
DS |
Down Syndrome |
CA |
Carbonic Anhydrase |
CAA |
Carbonic Anhydrase activator |
CAI |
Carbonic Anhydrase inhibitor |
CNS |
Central Nervous System |
CO2 |
carbon dioxide |
CP |
choroid plexuses |
CytC |
cytochrome C |
DS |
Down Syndrome |
ELISA |
enzyme-linked immunosorbent assay |
EPSP |
excitatory postsynaptic potential |
ERK |
extracellular signal-regulated kinase |
FDA |
Food And Drug Administration |
GABA |
gamma-aminobutyric acid |
HCO3- |
bicarbonate ion |
HD |
Huntington’s disease |
H2O2
|
hydrogen peroxide |
i.p. |
Intraperitoneal |
IPSP |
inhibitory postsynaptic potential |
MCI |
mild cognitive impairment |
MTZ |
Methazolamide |
MWM |
Morris water maze |
NINDS |
National Institute of Neurological Disorders and Stroke |
NFTS |
neurofibrillary tangles |
NMDA |
N-methyl-d-aspartate |
OSA |
obstructive sleep apnoea |
ROS |
reactive oxygen species |
WHO |
World Health Organization |
TgSwDI |
transgenic Swedish-Dutch-Iowa (mouse model of amyloidosis) |
Tg65DN |
transgenic mouse model of Down Syndrome |
ΔΨ |
mitochondrial membrane potential |